Trial Profile

A randomized, placebo-controlled Human Infection-Model Clinical Trial to Evaluate the Efficacy of Campylobacter jejuni/Escherichia coli Oral Vaccine Focusing on Enterotoxigenic E. coli (ETEC) Infections

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 12 May 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Traveller's diarrhoea-vaccine-Immuron/Naval Medical Research Center (Primary)
Indications Enterotoxigenic Escherichia coli infections; Traveller's diarrhoea
Focus Therapeutic Use

08 May 2023 According to an Immuron media release, the commencement is subject to ethics approval from the Institutional Review Board.
08 May 2023 Status changed from suspended to planning, according to an Immuron media release.
08 May 2023 According to an Immuron media release, the FDA has removed a clinical hold on the Investigational New Drug (IND) application allowing the NMRC to proceed this trial and now this trial is active.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com